No Data
Anika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Call Transcript
Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.
Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics with a Outperform and maintains $37 price target.
Anika Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 41.76% Barrington Research $37 → $37 Maintains Outperform 03/14/2024 41.76% Barrington Research
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)